NASDAQ
98.60USD
-2.89 (-2.85%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
21.4B
P/E
—
EPS
—
Beta
0.78
52W range
90.39-212.75
Day range
97.05–101.91
Open
101.53
Prev close
101.49
Volume
2.9M
Avg volume
3.9M
Dividend
0.00
IPO
2000-06-01
https://seekingalpha.com/article/4926882-alger-mid-cap-focus-fund-q2-2026-portfolio-review · 7/29/2026-0.80
https://seekingalpha.com/article/4916591-insmed-stock-extensive-phase-3-tpip-program-revenue-growth-q1-2026-strong-buy · 6/22/2026+1.00
https://www.benzinga.com/trading-ideas/movers/26/06/53271255/coreweave-stock-up-20-this-week-heres-everything-that-happened · 6/18/2026-0.50
https://www.marketbeat.com/instant-alerts/insmed-ceo-defends-brinsupri-launch-as-sales-surge-tpip-pipeline-gains-focus-2026-05-18/ · 5/18/2026+0.60
https://seekingalpha.com/article/4900280-insmed-incorporated-insm-q1-2026-earnings-call-transcript · 5/7/2026+0.00
https://www.zacks.com/stock/news/2896240/insmed-ends-brinsupri-development-in-skin-disease-post-study-failure · 4/8/2026-0.80
https://www.reuters.com/business/healthcare-pharmaceuticals/insmed-discontinues-development-skin-condition-drug-after-mid-stage-study-miss-2026-04-07/ · 4/7/2026-0.80
https://www.schaeffersresearch.com/content/analysis/2026/04/01/options-bulls-could-be-right-about-this-pharma-stock · 4/1/2026+0.60
https://www.fool.com/coverage/filings/2026/03/21/this-new-usd193-million-bet-targets-a-biotech-with-usd689-million-in-revenue-and-a-potential-turnaround-story/ · 3/21/2026+0.00
https://www.fool.com/coverage/filings/2026/03/21/this-usd116-million-buy-joins-a-360-stock-run-and-seemingly-signals-conviction-in-a-key-drug-launch/ · 3/21/2026+0.30
https://www.prnewswire.com/news-releases/insmed-to-present-at-march-2026-investor-conferences-302682778.html · 2/13/2026+0.10
https://247wallst.com/investing/2026/01/17/is-apellis-pharmaceuticals-fda-win-just-the-beginning/ · 1/17/2026+0.30
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
